查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1422888

2024-2032 年按技术（流式细胞仪、聚合酶链反应、下一代定序等）、应用、最终用户和地区分類的最小残留疾病检测市场

Minimal Residual Disease Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, and Others), Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球微小残留疾病（MRD）检测市场规模达21亿美元。展望未来， IMARC Group预计到2032年市场规模将达到51亿美元，2024-2032年复合年增长率（CAGR）为10.21% 。医疗保健产业的显着成长、广泛的研发 (R&D) 活动以及快速的技术进步是推动市场发展的一些关键因素。

微小残留疾病（MRD）检测是一种医学检测，用于检测和监测接受癌症治疗后患者体内可能残留的少量癌细胞。它广泛用于检测多种不同类型的癌症，例如白血病、淋巴瘤、多发性骨髓瘤和一些实体肿瘤。 MRD 检测采用高度灵敏的方法，包括细胞计数、聚合酶链反应 (PCR) 和新一代定序 (NGS)。它是监测癌症患者并帮助医生做出更明智的治疗决策的重要医学测试。 MRD 检测有助于早期发现疾病復发，提供更准确的治疗反应评估，并透过识别患者、改善患者结果和增强客製化治疗计划来指导个人化治疗计划。

微小残留疾病 (MRD) 检测市场趋势：

全球癌症盛行率不断上升是推动市场成长的关键因素之一。 MRD 检测是一种高度敏感的技术，广泛用于检测残留癌细胞，有助于早期指示疾病復发，并有助于指导个人化治疗计划。与此一致的是，MRD 检测作为一种诊断和监测工具，广泛应用于始于造血组织或免疫系统细胞的血液癌症，有利于市场成长。此外，消费者对个人化医疗的偏好转变，允许客製化治疗计划和监测，这是另一个成长诱导因素。除此之外，人工智慧(AI) 与MRD 测试的整合有助于识别模式、预测復发的可能性、提高诊断的准确性和有效性，并帮助临床医生就患者护理做出更明智的决策，从而提供了一种市场成长的动力。此外，越来越多地采用 NGS 技术来确定脱氧核糖核酸 (DNA) 或核糖核酸 (RNA) 的序列，以研究与疾病相关的遗传变异，这为市场创造了积极的前景。此外，人们越来越认识到识别体内可能导致癌症的致癌物质的重要性，这正在推动市场成长。其他因素，包括医疗保健行业的显着增长、广泛的研发 (R&D) 活动以及 MRD 检测项目领域投资的增加，预计将推动市场成长。

本报告回答的关键问题：

  • 迄今为止，全球微小残留疾病（MRD）检测市场表现如何，未来几年将如何表现？
  • 全球微小残留疾病（MRD）检测市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球微小残留疾病 (MRD) 检测市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的微小残留疾病 (MRD) 检测市场？
  • 什么是基于技术的市场分割？
  • 微小残留疾病（MRD）检测市场中哪一项技术最具吸引力？
  • 基于应用程式的市场区隔是什么？
  • 微小残留疾病（MRD）检测市场中最有吸引力的应用是什么？
  • 基于最终用户的市场区隔是什么？
  • 微小残留疾病 (MRD) 检测市场中哪一个对最终用户最具吸引力？
  • 全球微小残留疾病（MRD）检测市场的竞争结构如何？
  • 全球微小残留疾病（MRD）检测市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球微小残留疾病 (MRD) 检测市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依技术

  • 流式细胞仪
    • 市场走向
    • 市场预测
  • 聚合酶炼式反应 (PCR)
    • 市场走向
    • 市场预测
  • 次世代定序 (NGS)
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按应用

  • 血液系统恶性肿瘤
    • 市场走向
    • 关键环节
      • 白血病
      • 淋巴瘤
    • 市场预测
  • 实体肿瘤
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院和专科诊所
    • 市场走向
    • 市场预测
  • 诊断实验室
    • 市场走向
    • 市场预测
  • 学术及研究机构
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Adaptive Biotechnologies Corporation
    • Arup Laboratories Inc.
    • Bio-Rad Laboratories Inc.
    • Guardant Health
    • Invivoscribe Inc.
    • Natera Inc.
    • NeoGenomics Laboratories Inc.
    • Sysmex Corporation
Product Code: SR112024A7248

Abstract

The global minimal residual disease (MRD) testing market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.21% during 2024-2032. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.

Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.

Minimal Residual Disease (MRD) Testing Market Trends:

The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global minimal residual disease (MRD) testing market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on technology, application, and end user.

Technology Insights:

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next Generation Sequencing (NGS)

Others

The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the technology. This includes flow cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS) and others. According to the report, polymerase chain reaction (PCR) represented the largest segment.

Application Insights:

Hematological Malignancy

Leukemia

Lymphoma

Solid Tumors

A detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the application has also been provided in the report. This includes hematological malignancy (leukemia and lymphoma) and solid tumors. According to the report, hematological malignancy (leukemia and lymphoma) accounted for the largest market share.

End User Insights:

Hospitals and Speciality Clinics

Diagnostic Laboratories

Academic and Research Institutes

Others

The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the end user. This includes hospitals and speciality clinics, diagnostic laboratories, academic and research institutes, and others. According to the report, hospitals and speciality clinics represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for minimal residual disease (MRD) testing. Some of the factors driving the North America minimal residual disease (MRD) testing market included the increasing prevalence of cancer, significant growth in the healthcare industry, and extensive research and development (R&D) activities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global minimal residual disease (MRD) testing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.

Key Questions Answered in This Report:

  • How has the global minimal residual disease (MRD) testing market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global minimal residual disease (MRD) testing market?
  • What is the impact of each driver, restraint, and opportunity on the global minimal residual disease (MRD) testing market?
  • What are the key regional markets?
  • Which countries represent the most attractive minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the minimal residual disease (MRD) testing market?
  • What is the competitive structure of the global minimal residual disease (MRD) testing market?
  • Who are the key players/companies in the global minimal residual disease (MRD) testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Minimal Residual Disease (MRD) Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Flow Cytometry
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polymerase Chain Reaction (PCR)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Next Generation Sequencing (NGS)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hematological Malignancy
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Leukemia
      • 7.1.2.2 Lymphoma
    • 7.1.3 Market Forecast
  • 7.2 Solid Tumors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Speciality Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Academic and Research Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adaptive Biotechnologies Corporation
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Arup Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Bio-Rad Laboratories Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Guardant Health
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Invivoscribe Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Natera Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 NeoGenomics Laboratories Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Sysmex Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Minimal Residual Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Minimal Residual Disease Testing Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Minimal Residual Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Minimal Residual Disease Testing Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Minimal Residual Disease Testing Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Minimal Residual Disease Testing Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Minimal Residual Disease Testing Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Minimal Residual Disease Testing (Flow Cytometry) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Minimal Residual Disease Testing (Flow Cytometry) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Minimal Residual Disease Testing (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Minimal Residual Disease Testing (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Minimal Residual Disease Testing (Solid Tumors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Minimal Residual Disease Testing (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Minimal Residual Disease Testing (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Minimal Residual Disease Testing (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Minimal Residual Disease Testing Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Minimal Residual Disease Testing Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Minimal Residual Disease Testing Industry: Value Chain Analysis
  • Figure 79: Global: Minimal Residual Disease Testing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Minimal Residual Disease Testing Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Minimal Residual Disease Testing Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Minimal Residual Disease Testing Market: Competitive Structure
  • Table 7: Global: Minimal Residual Disease Testing Market: Key Players